This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Heart failure with preservedejectionfraction is a recognised outcome in patients with myocardialinfarction, although heart failure with reduced ejectionfraction is more common. Among patients with myocardialinfarction, a 1-SD increase in pulse pressure was associated with a 1.60-fold
Heart failure (HF) is one of the significant complications in patients with myocardialinfarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 Therefore, early identification of HF in high-risk populations, particularly post-MI, is essential for improving outcomes.
ET Main Tent (Hall B1) - A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial - Empagliflozin After Acute MyocardialInfarction: Results of the EMPACT-MI Trial - CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients (..)
Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major riskfactor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or riskfactors such as hypertension and dyslipidemia. [1]
42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant riskfactors. In the U.S.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content